Your browser doesn't support javascript.
loading
Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results.
Koreth, John; Kim, Haesook T; Lange, Paulina B; Poryanda, Samuel J; Reynolds, Carol G; Rai, Sharmila Chamling; Armand, Philippe; Cutler, Corey S; Ho, Vincent T; Glotzbecker, Brett; Yusuf, Rushdia; Nikiforow, Sarah; Chen, Yi-Bin; Dey, Bimalangshu; McMasters, Malgorzata; Ritz, Jerome; Blazar, Bruce R; Soiffer, Robert J; Antin, Joseph H; Alyea, Edwin P.
Afiliación
  • Koreth J; Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA john_koreth@dfci.harvard.edu.
  • Kim HT; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, MA.
  • Lange PB; Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
  • Poryanda SJ; Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
  • Reynolds CG; Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
  • Rai SC; Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
  • Armand P; Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
  • Cutler CS; Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
  • Ho VT; Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
  • Glotzbecker B; Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
  • Yusuf R; Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
  • Nikiforow S; Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
  • Chen YB; Massachusetts General Hospital Cancer Center, Boston, MA.
  • Dey B; Massachusetts General Hospital Cancer Center, Boston, MA.
  • McMasters M; Beth Israel Deaconess Hospital Cancer Center, Boston, MA.
  • Ritz J; Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
  • Blazar BR; University of Minnesota Masonic Cancer Center and Department of Pediatrics, Division of Blood and Marrow Transplantation, Minneapolis, MN, USA.
  • Soiffer RJ; Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
  • Antin JH; Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
  • Alyea EP; Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Haematologica ; 103(3): 522-530, 2018 03.
Article en En | MEDLINE | ID: mdl-29326124
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapia de Inmunosupresión / Trasplante de Células Madre Hematopoyéticas / Acondicionamiento Pretrasplante / Bortezomib Tipo de estudio: Clinical_trials / Etiology_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2018 Tipo del documento: Article País de afiliación: Marruecos Pais de publicación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapia de Inmunosupresión / Trasplante de Células Madre Hematopoyéticas / Acondicionamiento Pretrasplante / Bortezomib Tipo de estudio: Clinical_trials / Etiology_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Año: 2018 Tipo del documento: Article País de afiliación: Marruecos Pais de publicación: Italia